![](images/graphics/blank.gif)
Biological evaluation of novel gemcitabine analog in patient-derived xenograft models of pancreatic cancer
3
lượt xem 2
download
lượt xem 2
download
![](https://tailieu.vn/static/b2013az/templates/version1/default/images/down16x21.png)
Gemcitabine (Gem) has been a standard first-line drug for pancreatic cancer (PCa) treatment; however, Gem’s rapid metabolism and systemic instability (short half-life) limit its clinical outcome. The objective of this study was to modify Gem into a more stable form called 4-(N)-stearoyl-gemcitabine (4NSG) and evaluate its therapeutic efficacy in patient-derived xenograft (PDX) models from PCa of Black and White patients.
Chủ đề:
Bình luận(0) Đăng nhập để gửi bình luận!
![](images/graphics/blank.gif)
CÓ THỂ BẠN MUỐN DOWNLOAD